TFRC and prostate cancer: An alternative strategy for FZD6 inhibition is to conjugate siRNA targeting FZD6 with aptamers directed against prostate cancer antigens such as PSMA (prostate-specific membrane antigen) [46] or TfR1 (Transferrin Receptor 1) [47].